EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Multidrug therapy does not eliminate the risk of ocular disability in leprosy

Matthew Willis iD

PLOS Neglected Tropical Diseases · 06.11.2026 · 20 (11) · e0014859

DOI: 10.1371/journal.pntd.0014859 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, online erschienen am 06.11.2026. Verfasst von Matthew Willis. Beteiligte Einrichtung: Department of Global Health, Institute of Public Health and Nursing Research, University of Bremen, Bremen, Germany. Hauptthemen laut MEDLINE: Leprosy, Leprostatic Agents, Eye Diseases. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Whilst multidrug therapy can provide a microbiological cure for leprosy infection, it does not reverse nerve damage that is already established, nor remove the risk of the occurrence of future ocular complications. Ocular conditions associated with leprosy such as lagophthalmos, reduced corneal sensation, exposure keratopathy, uveitis and other sight and eye threatening conditions may be present at diagnosis, develop during treatment, or even progress long after treatment has already been completed. Existing guidance already recommends eye assessment during treatment, but continuity after treatment varies between settings. This viewpoint therefore argues for implementing these recommendations through a minimum pathway which links assessment during treatment to risk-stratified follow-up after treatment completion, clear referral responsibilities, supported self-care and monitoring, and routine assessment of visual outcomes in paper or electronic records. To be successful these measures should be integrated within existing leprosy, primary-care and eye-care services, with links to non-communicable disease programmes where these can support long-term care. Achieving zero disability due to leprosy requires recognising that treatment completion is not the end of ocular risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LeprosyLeprostatic AgentsEye DiseasesHumansDrug Therapy, Combination

Substanzen

Leprostatic Agents

Autor:innen und Institutionen

  • Department of Global Health, Institute of Public Health and Nursing Research, University of Bremen, Bremen, Germany.
  • Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom.

ORCID-Profile: Matthew Willis

Zitieren

APA

Willis, M. (2026). Multidrug therapy does not eliminate the risk of ocular disability in leprosy. PLOS Neglected Tropical Diseases, 20(11), e0014859. https://doi.org/10.1371/journal.pntd.0014859

Vancouver

Willis M. Multidrug therapy does not eliminate the risk of ocular disability in leprosy. PLOS Neglected Tropical Diseases. 2026;20(11):e0014859. doi:10.1371/journal.pntd.0014859

BibTeX
@article{Willis2026,
  author = {Willis, Matthew},
  title = {Multidrug therapy does not eliminate the risk of ocular disability in leprosy},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2026},
  volume = {20},
  number = {11},
  pages = {e0014859},
  doi = {10.1371/journal.pntd.0014859}
}
Kostenlos starten →